TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

This study is testing a combination of a liver artery procedure (called TACE, where blood supply to liver tumors is blocked) along with immune checkpoint inhibitor drugs for people with liver cancer (hepatocellular carcinoma, or HCC). **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of liver cancer (HCC) - You have not received any prior systemic therapy or immunotherapy for your liver cancer - You are in good enough physical condition (able to carry out daily activities) - You are eligible for the TACE procedure - You have at least one measurable tumor in the liver **You may NOT be eligible if...** - You have a history of kidney disease or nephrotic syndrome - Your cancer has spread outside the liver - You have significant heart problems (unstable angina, heart failure, or poorly controlled irregular heartbeat) - You have a history of bleeding disorders - You have previously received immunotherapy (anti-PD-1, anti-PD-L1, or anti-CTLA-4) - You have had prior liver-directed treatments (TACE, TAE, HAIC, or TARE) or systemic cancer treatment Talk to your doctor to see if this trial is right for you.